The identification of actionable tumor antigens is indispensable for the development of
several cancer immunotherapies, including T cell receptor–transduced T cells and patient …

Malignant transformation of cells depends on accumulation of DNA damage. Over the past
years we have learned that the T cell–based immune system frequently responds to the …

Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving
to be effective at restoring T cell-mediated immune responses that can lead to marked and …

Mass spectrometry is unmatched in its versatility for studying practically any aspect of the
proteome. Because the foundations of mass spectrometry-based proteomics are complex …

Major histocompatibility complex II (MHC II) molecules play a vital role in the onset and
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Accurate prediction of antigen presentation by human leukocyte antigen (HLA) class II
molecules would be valuable for vaccine development and cancer immunotherapies …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Predictions of epitopes presented by class II human leukocyte antigen molecules (HLA-II)
have limited accuracy, restricting vaccine and therapy design. Here we combined unbiased …